Genetic analysis links immune cell profiles to kidney cancer therapy outcomes
A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy found ...
Healio17h
VIDEO: Trial builds on current microsatellite instability-high colorectal cancer therapy
In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...
PharmiWeb12h
Global PD-L1 Biomarker Testing Market to Reach USD…
The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period.PD-L1 ...
stocknews20h
3 Healthcare Stocks Tackling America’s Biggest Medical Challenges
From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...